The efficacy of dihydropyridine calcium channel blockers for treating hypertension appears to be similar, but a variety of factors, including patient characteristics, tolerability and pharmacokinetic properties, may influence treatment adherence and outcome. We aimed to evaluate treatment adherence in clinical practice among older hypertensive adults (50+ years) prescribed amlodipine or felodipine for the first time as part of the California Medicaid (Medi-Cal) program. We used a retrospective, matched, cohort-analysis design. Over 1 year, patients prescribed amlodipine were 21% less likely to discontinue study treatment than those prescribed felodipine. Discontinuation tended to occur early, with 20% and 30% of amlodipine and felodipine patients, respectively, discontinuing treatment after one prescription. A non-significant difference in favour of amlodipine was demonstrated for anti-anginal medication use among patients taking these drugs at baseline. This study suggests that use of amlodipine may be associated with improved adherence, compared with felodipine, among older out-patients in the Medi-Cal program.
Introduction
Pharmaceutical spending has grown rapidly in recent years, and in 2001 represented 10% of all healthcare spending (US$141 billion). 1 In an attempt to manage drug costs, a variety of payers, including privately managed-care plans and US government programs, such as Medicaid and the Department of Veterans' Affairs, are using formularies.
With formularies, access to certain medications may be restricted (closed type) or permitted (open type), although with the latter, use may be controlled through prior authorization or via treatment guidelines. When some new medications become available they may be perceived as being equivalent to existing products from the same therapeutic class. In this instance the acquisition cost of a product may become an overriding factor in obtaining a preferred status on formularies.
Calcium channel blocking agents, which are commonly used to treat hypertension and/or angina pectoris, belong to a drug class that comprises a relatively large portion of cardiovascular drug spending. Two widely prescribed once-daily dihydropyridine calcium channel blockers are amlodipine and felodipine. Some formularies have selected felodipine as the preferred medication, 2,3 while others have chosen amlodipine. 4 For the formularies at Madigan Army Medical Center and the Newington Veterans' Affairs Medical Center, cost was a major consideration, 2,3 since felodipine is less expensive on a per milligram basis. 5 At Patrick Air Force Base, amlodipine was selected due to its longer half-life and the fact that this product has a Food and Drug Administration-approved indication for angina. 4 The limited number of comparative studies of these medications has demonstrated mixed results, with one reporting that amlodipine is more effective than felodipine 6 in terms of lowering blood pressure, and another showing similar levels of efficacy. 7 The applicability of short-term data on blood pressure lowering from clinical trials to treatment effectiveness in typical practice may, however, be limited. A variety of factors in addition to efficacy (including the characteristics of the patients treated, the doses prescribed and titration schedules, tolerability and pharmacokinetic properties) may influence the ultimate outcomes of treatment with amlodipine or felodipine. In addition, treatment outcomes can be influenced by differences in rates of adherence to medication, which cannot be easily assessed in clinical trials.
We undertook a retrospective analysis using health insurance claims data to explore whether there are differences in clinical practice between rates of treatment adherence among older adults treated with amlodipine versus felodipine.
Patients and methods

OVERVIEW OF DESIGN
This study used a retrospective cohort design and detailed claims data for a 10% random sample of California Medicaid ('Medi-Cal') recipients. Patients aged 50 years and older who were initially prescribed amlodipine or felodipine during a designated index period were selected. Two amlodipine patients were matched to one felodipine patient on the basis of selected characteristics. Analyses were undertaken over a 1-year period following the start of treatment with either agent.
DATA SOURCE
The data for this study were provided by the California Department of Health Services and consisted of enrolment and administrative paid claims data for a 10% random sample of Medi-Cal recipients covering the period from October 1994 through December 1998. State Medicaid programs, including Medi-Cal, provide healthcare services to poor, elderly and disabled individuals, with the federal government contributing a share of the cost (50% in California). In 1998, the Medi-Cal program served over 5 million persons, and total healthcare payments exceeded $14 billion.
The Medi-Cal patient enrolment file detailed age, gender and race, as well as whether or not the recipient was eligible for Medi-Cal services in each study month. The claims files included details on prescriptions filled (National Drug Code, dispense date, quantity of medication prescribed, therapy days supplied), out-patient services (date of service, type of service, one International Classification of Diseases, 9th Revision, Clinical Modification [ICD-9-CM] diagnosis code) and institutional services (type of facility, admission and discharge dates, one primary and one secondary ICD-9-CM diagnosis code, procedures performed).
COHORT SELECTION
Patients were selected for study inclusion if they: received at least one prescription for amlodipine or felodipine for 30 days or more between 1 February 1995 and 31 December 1997; were 50 years of age or older; were Medi-Cal eligible from 4 months before until 12 months after the index prescription; and had at least 12 months of follow-up data as determined by the eligibility file and paid claims in each calendar quarter. The first of the two drugs prescribed between 1 February 1995 and 31 December 1997 determined the cohort to which a patient was assigned (i.e. amlodipine or felodipine). We excluded patients who had received the particular study medication in the 4-month pre-index ('baseline') period, since our focus was on patients receiving these therapies for the first time.
Two amlodipine patients were matched to one felodipine patient based on a diagnosis (primary or secondary) of each of the following cardiovascular comorbidities: angina and ischaemic heart disease, congestive heart failure or diabetes. The 2:1 matching algorithm was used to increase the statistical power. Patients were also matched on comorbidity using the Deyo et al. 8 adaption of the Charlson comorbidity index, as well as whether or not they were newly starting antihypertensive therapy. Amlodipine patients were selected randomly when more than two individuals were available to match each felodipine subject.
STUDY MEASURES
Measures of adherence to therapy included: the proportion of patients with no prescriptions for study therapy in the last 6 months of the follow-up period (i.e. 'discontinuation'); the percentage with more than 15 days between refills (i.e. 'interruption'); and the number of days during the 12-month follow-up period on which study medication was available (i.e. covered days, or 'persistence'). For patients who discontinued study therapy, we examined whether they terminated all anti-hypertensive drug therapy. We examined early discontinuation by assessing the proportion of patients who did not fill a second prescription for study medication. Similar measures of adherence have been used in other published studies of compliance with pharmaceutical therapy. 9 -14 The reduction in use of anti-anginal medication after receipt of study medication was also examined among patients who had such medications dispensed during the baseline period.
DATA ANALYSES AND STATISTICAL METHODS
The amlodipine and felodipine cohorts were compared on the basis of non-matched variables, including: age; sex; the presence of hypertension, hyperlipidaemia or cerebrovascular accident; resource utilization in the 4 months prior to the start of study therapy; use of other anti-hypertensive therapies; and the total number of unique medications available at index. With the exception of acute myocardial infarction and cerebrovascular accident, which were evaluated only during the 4 months prior to the index date, the presence of comorbidities was evaluated over each patient's entire 16month study period. Alternative analyses that assessed all cardiovascular conditions only over the 4-month pre-index period yielded similar findings and are therefore not reported.
Comparisons of non-matched baseline characteristics were undertaken using paired sample techniques. Conditional logistic regression 15, 16 was used to evaluate differences between groups in the proportions of patients who were male, who had Adherence to calcium channel blocker therapy hypertension, hyperlipidaemia or cerebrovascular accident, or who were hospitalized or admitted to a nursing home. Differences in mean age and the number of unique medications dispensed were assessed using weighted analysis of variance techniques.
Analyses of the likelihood of study therapy discontinuation and likelihood of interruption in treatment were undertaken using conditional logistic regression. This test was also used to evaluate changes in antianginal medication use among patients who had such medications dispensed during the baseline period. The difference between the cohorts in persistence was evaluated using weighted analysis of variance techniques. Multivariate analyses that controlled for non-matched factors that differed between study groups were also undertaken, but had no effect on our findings and therefore are not reported.
All analyses of data were conducted using PC-SAS version 8 (SAS Institute Inc., Cary, NC, USA). A P-value < 0.05 was considered significant.
Results
PATIENT CHARACTERISTICS
A total of 413 patients receiving felodipine met the entry criteria for this study. From a pool of 6238 eligible amlodipine patients, 826 were randomly matched (2:1) to the felodipine patients. Aside from the matching variables which were similar (angina and ischaemic heart disease, congestive heart failure, diabetes, Charlson comorbidity index > zero and whether or not patients were newly starting anti-hypertensive therapy), hyperlipidaemia was more common among amlodipine patients (Table 1) . Fifteen percent and 17% of patients receiving amlodipine and felodipine, respectively, were also receiving anti-anginal medication during the baseline period.
STUDY OUTCOMES
Significantly fewer amlodipine patients discontinued study therapy compared with those receiving felodipine ( Table 2) . Discontinuation tended to occur early, with 20% of amlodipine patients and 30% of felodipine patients discontinuing treatment after filling only a single prescription (P < 0.05). There were, however, no differences between groups in the discontinuation of all anti-hypertensive therapies (14% and 15% for amlodipine and felodipine, respectively).
There were no differences in persistence (i.e. 'covered days'; 53% of study days with amlodipine versus 50% for the felodipine group) or in treatment interruption between the two groups.
Use of anti-anginal medication was lower in the amlodipine group versus the felodipine group among those who were dispensed these drugs at baseline, although this difference was not significant (an odds ratio for discontinuation of 1.71; 95% CI: 0.77 -3.79).
Discussion
To better understand adherence to two oncedaily dihydropyridine calcium channel blockers in actual clinical practice we used a retrospective matched cohort design and detailed Medi-Cal claims data.
Our findings of better adherence for amlodipine compared with felodipine are consistent with those of a recent large Canadian study. 16 In that study, drug prescription patterns and medical resource consumption were assessed for a 20% random sample of elderly persons in Quebec. Approximately 7800 patients aged 65 years and over, without angina and receiving amlodipine (n = 5188) or felodipine (n = 2630) between 1990 and 1997, were eligible for study. The Canadian findings showed that felodipine patients were 27% more likely to discontinue treatment than the amlodipine patients. 17 While the precise reason(s) for differences in therapy discontinuation rates cannot be ascertained from retrospective database studies, non-adherence may reflect an inadequate response to therapy and/or sideeffects. It should be noted that over half of the patients in both groups who discontinued treatment went on to receive other antihypertensive therapies. While this is perhaps less troublesome than stopping antihypertensive treatment altogether, the need to change medication may be inconvenient for patients and increase the overall costs of care.
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There are several limitations to our study. First, there may be confounding factors that affect adherence to anti-hypertensive therapy for which statistical control was not possible. Such factors could include the severity of angina as well as blood pressure levels. Secondly, while attempts were made to match study groups on measures of cardiovascular disease (e.g. congestive heart failure, diabetes, angina) and overall health status (Charlson comorbidity index), varying severity of angina and coronary heart disease may have influenced our results. Thirdly, adherence to therapy may vary based on the success in lowering blood pressure levels, which we could not ascertain using our data.
Administrative claims data accurately reflect medications dispensed, 18 but refilling prescriptions does not necessarily indicate drug consumption. Nevertheless, analyses of prescription drug records are commonly used to evaluate patient adherence and drug exposure for large populations. Use of claims data for this purpose avoids pill-counting and patient recall, which are subject to their own biases. Similar administrative claims data have been used in several published studies of medication usage patterns and compliance. 9 -14 We used ICD-9-CM diagnosis codes contained on medical claims to identify selected cardiovascular conditions in the study population. While this methodology is becoming increasingly used, it is important to note that the validity of administrative claims for this purpose has been established for relatively few disease conditions. It is unclear what effect, if any, possible misclassification bias would have had on our findings.
Finally, the population examined consisted of Medicaid-eligible older adults. It is, therefore, possible that our findings would not be applicable to younger working individuals or higher income elderly persons, particularly since Medicare does not currently cover outpatient medication. One might expect rates of medication adherence to be lower among patients without prescription drug coverage, although it is uncertain whether this would have influenced the differences in medication 238 J Menzin, K Lang, WJ Elliott et al. Adherence to calcium channel blocker therapy Amlodipine and felodipine are viewed as pharmacologically similar, but this study suggests amlodipine may be associated with improved adherence in an older adult Medicaid population. This factor may be important for therapeutic decision-making.
